Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature
- PMID: 8212834
- DOI: 10.1016/0264-410x(93)90375-8
Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature
Abstract
Health authorities tend to favour an increase of the antigen dose in inactivated influenza vaccines from < or = 10 micrograms haemagglutinin (HA) per vaccine strain to 15 micrograms HA/strain. The increased dose is expected to yield a meaningful increase in the number of subjects to be protected after vaccination. To verify this expectation, we have reviewed 20 published reports (1978-1991) of serological studies in which anti-HA-IgG antibody after different doses was measured. In the review, stratification groups of previously primed subjects were formed and the antibody response was estimated for doses of 10 and 15 micrograms HA by linear k*2-chi 2 model. Despite a considerable heterogenicity of study populations, study designs, vaccine types and strains, and antibody assays, the results were consistent in revealing high protection rates (> or = 75%) for a 10 micrograms HA dose of influenza A vaccine components. For both response and protection rates, an increase of the antigenic load from 10 to 15 micrograms HA was not associated with a meaningful increase of seroresponse: in 38 out of 39 stratification groups, the increase of response and/or protection rate varied between -9% and +8%, with a median of 1.5%. These results do not justify the expectation that a vaccine dose of 15 micrograms HA per strain would be clinically superior to a dose of 10 micrograms HA. Only in a group of immune-compromised patients on chronic intermittent haemodialysis were results in favour of a higher dose found, which may justify further evaluation in this special population.
Similar articles
-
A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection.J Hyg (Lond). 1983 Feb;90(1):107-15. doi: 10.1017/s0022172400063907. J Hyg (Lond). 1983. PMID: 6822725 Free PMC article.
-
Clinico-immunologic and allergologic studies with the inactivated influenza virus vaccine purified and concentrated by gradient centrifugation.Acta Virol. 1988 Nov;32(6):494-502. Acta Virol. 1988. PMID: 2906221
-
High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults.J Clin Microbiol. 1994 Oct;32(10):2468-73. doi: 10.1128/jcm.32.10.2468-2473.1994. J Clin Microbiol. 1994. PMID: 7814484 Free PMC article. Clinical Trial.
-
Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Jpn J Infect Dis. 2016. PMID: 27212584 Review.
-
Seasonal influenza vaccines.Curr Top Microbiol Immunol. 2009;333:43-82. doi: 10.1007/978-3-540-92165-3_3. Curr Top Microbiol Immunol. 2009. PMID: 19768400 Review.
Cited by
-
Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine.Influenza Other Respir Viruses. 2008 May;2(3):93-8. doi: 10.1111/j.1750-2659.2008.00039.x. Influenza Other Respir Viruses. 2008. PMID: 19453468 Free PMC article. Clinical Trial.
-
Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination.Influenza Other Respir Viruses. 2007 Jul;1(4):147-56. doi: 10.1111/j.1750-2659.2007.00017.x. Influenza Other Respir Viruses. 2007. PMID: 18458742 Free PMC article.
-
Rectal immunization for induction of specific antibody in the genital tract of women.J Clin Immunol. 1997 Sep;17(5):370-9. doi: 10.1023/a:1027312223474. J Clin Immunol. 1997. PMID: 9327336 Clinical Trial.
-
BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.Thorax. 2001 Dec;56 Suppl 4(Suppl 4):IV1-64. doi: 10.1136/thorax.56.suppl_4.iv1. Thorax. 2001. PMID: 11713364 Free PMC article. No abstract available.
-
Hemagglutination inhibiting antibody persistence 1 year after influenza vaccination in Korean children and adolescents.Hum Vaccin Immunother. 2017 Apr 3;13(4):895-902. doi: 10.1080/21645515.2016.1259044. Epub 2016 Dec 1. Hum Vaccin Immunother. 2017. PMID: 27905835 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical